Shares slid as investors struggled to reconcile a blockbuster quarter with lingering doubts about the dental-products maker's durability. Envista Holdings posted adjusted earnings of $0.41 per share on revenue of $730.5 million in Q2 2026 , topping analyst expectations of $0.34 on $716.6 million in sales . The company lifted its full-year adjusted EPS guidance to $1.50–$1.55, well above the Street consensus of $1.43 . Yet the stock is sitting at $26.90, down 6% from its prior close — a pattern that echoes Q1, when shares fell 7.25% after hours despite a similar beat .

  • The Numbers Were Strong Across the Board — Revenue, Margins, and Cash Flow All Improved. Core sales grew 5%, with Specialty Products up 3.1% and the Equipment & Consumables segment surging 8.5% . Adjusted EBITDA hit $108 million, up 28% year-over-year, with margins expanding 230 basis points (about 2.3 percentage points) to 14.7% . Free cash flow reached $105 million, compared with $76 million a year ago . For a company that posted just $1.19 in adjusted EPS for all of 2025, delivering $0.41 in a single quarter is a meaningful acceleration.

  • A One-Time Tariff Refund Complicates the Profit Picture. Adjusted results exclude a $12.6 million tariff refund that boosted GAAP profits — and investors should separate this item when judging the underlying earnings trend . That refund inflates the headline operating margin jump to 11% from 6.8% a year ago, making it harder to gauge how much improvement was organic.

  • Wall Street Sees Growth Slowing After a Hot Streak. Analysts expect revenue growth to decelerate to just 1.1% over the next twelve months, a sharp slowdown that suggests potential demand challenges . Envista's five-year annualized revenue growth sits at only 3.4% , reinforcing skepticism that recent momentum is structural rather than cyclical.

  • The Sell-the-News Habit Persists Despite a Turnaround Story. BMO Capital initiated coverage with a Market Perform rating and a $27 target, noting the turnaround is real and CEO credibility has grown . Evercore ISI raised its target to $33 , while Barclays trimmed its target to $32 but kept an Overweight rating . Envista repurchased 2.4 million shares for ~$59 million in Q2, with $283 million remaining under its buyback . But first-half free cash flow conversion — the share of earnings converted to actual cash — was just 70.7%, below the company's ~100% annual target .

The bottom line: Envista is executing better than it has in years, but at roughly 17.5x its new midpoint EPS, the stock's discount to peers reflects a market that wants proof the improvement lasts beyond favorable comparisons. An Investor Day on September 17 could be the next catalyst — or the next sell-the-news event.